8-K: Prothena Halts Birtamimab Development After Phase 3 Trial Fails Primary Endpoint in AL Amyloidosis

Prothena Corporation plc announced the discontinuation of its birtamimab program following the failure of its Phase 3 AFFIRM-AL clinical trial to meet its primary and secondary endpoints in patients with AL amyloidosis.

Summary

• Prothena Corporation plc's Phase 3 AFFIRM-AL clinical trial for birtamimab in AL amyloidosis patients did not meet its primary endpoint of time to all-cause mortality (HR=0.915, p-value=0.7680).
• Neither of the secondary endpoints, 6-minute walk test distance (nominal p-value=0.5288) and Short Form-36 version 2 Physical Component Score (nominal p-value=0.9597), were met.
• As a result, Prothena will discontinue all development of birtamimab, including stopping the open-label extension of the AFFIRM-AL clinical trial.
• The company plans to decrease ongoing operating expenses, including an expected substantial reduction in organizational size, with further details anticipated in June.
• Birtamimab was generally safe and well-tolerated, consistent with its established safety profile.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the complete failure of a Phase 3 clinical trial for a key drug candidate, leading to its discontinuation and anticipated significant workforce reductions. While other pipeline programs exist, this represents a major setback for the company's near-term prospects and financial stability.

Positives

• Birtamimab demonstrated a generally safe and well-tolerated profile, consistent with previous findings.
• Prothena maintains a pipeline of other investigational therapeutics with several upcoming data readouts and program updates expected over the next 18 months.

Negatives

• The Phase 3 AFFIRM-AL clinical trial for birtamimab failed to meet its primary endpoint of time to all-cause mortality.
• All secondary endpoints for the birtamimab trial were also not met.
• Prothena will discontinue all development of birtamimab, representing a significant setback for the program.
• The company expects a substantial reduction in organizational size as part of efforts to decrease operating expenses.

Risks

• Uncertainties related to the completion of operational and financial closing procedures.
• Potential audit adjustments and other developments that may require adjustments to preliminary financial results.
• Risks associated with the continued advancement and success of other discovery, preclinical, and clinical pipeline programs.
• Uncertainties regarding the timing and scope of planned activities to reduce ongoing operating expenses and potential workforce reductions.
• Risks inherent in the evaluation of business options and the finalization of related plans.

Future Outlook

Prothena plans to reduce ongoing operating expenses, including a substantial workforce reduction, with details expected in June. The company anticipates several key data readouts and pipeline updates over the next 18 months, including initial data from the Phase 1 ASCENT clinical trials on PRX012 in Alzheimer's disease in August 2025, and program updates from partners Roche (mid-year), Novo Nordisk (2H25), and Bristol Myers Squibb (2026). The company and board are evaluating business options in the best interest of shareholders.

Management Comments

• "This is not the outcome that we expected, and we are surprised and disappointed by these results for patients, their families and caregivers, and for the entire AL amyloidosis community." Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
• "With these results, we believe that the most appropriate action is to discontinue all development of birtamimab." Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
• "While we are all disappointed with todays results, Prothena has meaningful data readouts and pipeline updates over the next 18 months." Daniel G. Welch, Chair of Prothena's Board of Directors.

Industry Context

The failure of a late-stage clinical trial for a drug targeting a rare disease like AL amyloidosis highlights the inherent risks in biotechnology and drug development. While a significant setback for Prothena's AL amyloidosis program, the company's continued focus on its broader pipeline, particularly in neurodegenerative diseases like Alzheimer's and Parkinson's, aligns with ongoing industry efforts to address these challenging conditions. The discontinuation allows for reallocation of resources to other promising programs, a common strategic pivot in the biotech sector following clinical failures.

Stakeholder Impact

• Shareholders: Negative impact due to the failure of a late-stage clinical asset and potential share price decline, though cost reductions may mitigate some long-term concerns.
• Employees: Significant negative impact due to an expected substantial workforce reduction.
• Patients and Caregivers: Disappointment for the AL amyloidosis community as a potential treatment option is discontinued.
• Investors and Analysts: Will need to re-evaluate Prothena's valuation based on its remaining pipeline and reduced operational footprint.

Next Steps

• Discontinue the open-label extension of the AFFIRM-AL clinical trial for birtamimab.
• Decrease ongoing operating expenses, including an expected substantial workforce reduction.
• Provide a further update on plans to reduce operating expenses in June.
• Evaluate business options with financial advisors in the best interest of shareholders.
• Communicate results of the business options review once analysis and plans are finalized.
• Anticipate initial data from the Phase 1 ASCENT clinical trials on PRX012 in Alzheimer's disease in August 2025.
• Expect program updates from partners at Roche mid-year 2025.
• Expect program updates from partners at Novo Nordisk in 2H25.
• Expect program updates from partners at Bristol Myers Squibb in 2026.

Key Dates

Recommendation

Keywords

Prothena, PRTA, AL amyloidosis, birtamimab, AFFIRM-AL, clinical trial failure, Phase 3, biotechnology, neurodegenerative diseases, drug development, pipeline, workforce reduction